These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37725500)

  • 1. Prevalence of Antibodies to COVID-19 Due to Infection or Vaccination in US Adults.
    Stout RL; Rigatti SJ
    J Insur Med; 2023 Jul; 50(1):49-53. PubMed ID: 37725500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Antibodies to COVID-19 Due to Infection or Vaccination in US Adults.
    Stout RL; Rigatti SJ
    J Insur Med; 2023 May; ():. PubMed ID: 37230952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021.
    Busch MP; Stramer SL; Stone M; Yu EA; Grebe E; Notari E; Saa P; Ferg R; Manrique IM; Weil N; Fink RV; Levy ME; Green V; Cyrus S; Williamson PC; Haynes J; Groves J; Krysztof D; Custer B; Kleinman S; Biggerstaff BJ; Opsomer JD; Jones JM
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S254-S263. PubMed ID: 35684973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021.
    Kao S-YZ; Nycz E; Benoit TJ; Clarke KEN; Jones JM
    Microbiol Spectr; 2024 Aug; 12(8):e0012324. PubMed ID: 38869287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system.
    Chervo TC; Elkin EP; Nugent JR; Valice E; Amsden LB; Ergas IJ; Munneke JR; Flores M; Saelee GN; Hsiao CA; Schapiro JM; Quesenberry CP; Corley DA; Habel LA; Kushi LH; Skarbinski J
    PLoS One; 2024; 19(6):e0303303. PubMed ID: 38900738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.
    Bajema KL; Wiegand RE; Cuffe K; Patel SV; Iachan R; Lim T; Lee A; Moyse D; Havers FP; Harding L; Fry AM; Hall AJ; Martin K; Biel M; Deng Y; Meyer WA; Mathur M; Kyle T; Gundlapalli AV; Thornburg NJ; Petersen LR; Edens C
    JAMA Intern Med; 2021 Apr; 181(4):450-460. PubMed ID: 33231628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
    Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Newborn Dried Blood Spots to Ascertain Seroprevalence of SARS-CoV-2 Antibodies Among Individuals Giving Birth in New York State, November 2019 to November 2021.
    Damjanovic A; Styer LM; Nemeth K; Yauney E; Rock JM; Bievenue R; Hoen R; Ehrbar D; Kay DM; Caggana M; Parker MM
    JAMA Netw Open; 2022 Aug; 5(8):e2227995. PubMed ID: 35994287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
    Stringhini S; Zaballa ME; Pullen N; Perez-Saez J; de Mestral C; Loizeau AJ; Lamour J; Pennacchio F; Wisniak A; Dumont R; Baysson H; Richard V; Lorthe E; Semaani C; Balavoine JF; Pittet D; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe K; Kaiser L; Guessous I;
    Euro Surveill; 2021 Oct; 26(43):. PubMed ID: 34713799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and vaccine antibody prevalence in a multi-ethnic inner-city antenatal population: A cross-sectional surveillance study.
    Andreeva D; Gill C; Brockbank A; Hejmej J; Conti-Ramsden F; Doores KJ; Seed PT; Poston L;
    BJOG; 2023 Aug; 130(9):1135-1144. PubMed ID: 37113111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.
    Zinszer K; McKinnon B; Bourque N; Pierce L; Saucier A; Otis A; Cheriet I; Papenburg J; Hamelin MÈ; Charland K; Carbonneau J; Zahreddine M; Savard A; Fortin G; Apostolatos A; Haley N; Ratté N; Laurin I; Nguyen CT; Conrod P; Boivin G; De Serres G; Quach C
    JAMA Netw Open; 2021 Nov; 4(11):e2135975. PubMed ID: 34812845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of SARS-CoV-2 seroprevalence in relation to natural infection and vaccination between October 2020 and September 2021 in the Czech Republic: a prospective national cohort study.
    Thon V; Piler P; Pavlík T; Andrýsková L; Doležel K; Kostka D; Pikhart H; Bobák M; Klánová J
    BMJ Open; 2023 Mar; 13(3):e068258. PubMed ID: 36898746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.